The role of secondary cytoreductive surgery for recurrent ovarian cancer

摘要: Objective. The aim of this study was to assess the survival benefit salvage surgical cytoreduction in patients with recurrent ovarian cancer and compare outcome chemotherapy alone. Methods. Seventy-five were reviewed for possible benefits therapy. Forty-four had surgery 31 alone treatment gross disease. All been clinically free disease more than 6 months from completion primary treatment. Results. A macroscopically complete obtained 34 (77%) patients. Survival significantly longer who compared those (P = 0.03). Moreover, completely cytoreduced not operated 0.007 P 0.005, respectively). Conclusions. Macroscopically improves further However, we remain need evaluate debulkability tumor before maximize minimize number ineffective surgeries.